Evaluation and study the effect of asymmetric dimethylarginine in chronic renal failure patients treated by hemodialysis

Abstract

In term of morbidity and mortality, chronic renal failure ( CRF) is among the most serious chronic disease which result from the permanent loss of kidney function and without a regular course of dialysis or kidney transplantation , the disease is fatal. Recent studies indicated that in end stage renal disease(ESRD) , there is a new cardiovascular risk factors include: Homocysteine (Hcy) and Asymmetric dimethylarginine(ADMA). Hyperhomosyct(e)inaemia (HHC) a consistent finding in uraemic patients is now widely recognized as an independent risk factor for vascular disease . HHC is associated with an increased risk of myocardial infarction, stroke, and venous thromboembolism. The other risk factor asymmetric dimethyl arginine (ADMA), endogenous inhibitor of nitric oxide synthase (NOS) is also elevated in chronic renal failure (CRF). The aim of this study was to determine the effect of ADMA concentration on renal function in hemodialysis patients (HD).also urea and creatinine and electrolyte was examined. Blood samples were obtained from 20 apparently healthy subjects (10 male and 10 female), patients with renal failure, treated by hemodialysis, 25(12 male and 13 female). Plasma concentration of ADMA was significantly higher than those of control (P-value ≥ 0.05).